When deciding whether to use ovarian function suppression in premenopausal patients with triple positive (ER+ HER2+) tumors, does HER2 status or response to neoadjuvant influence your decision?

What factors influence your decision regarding endocrine therapy with our without ovarian function suppression in triple positive tumors?